Company Profile

4E Therapeutics Inc
Profile last edited on: 1/3/2022      CAGE: 8AL88      UEI: TLVMVN8EFNU3

Business Identifier: Novel treatments for neuropathic pain
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3800 North Lamar Boulevard Suite 200
Austin, TX 78703
   (512) 695-7563
Location: Single
Congr. District: 25
County: Travis

Public Profile

4E Therapeutics, Inc. is a neuroscience company structured around developing a non-opioid therapeutics for neuropathic pain in a concerted effort to stem the tide of the opiod addition crisis. Affecting some 10% of the population in the US, neuropathic pain is a leading cause of disability with few options that actually work and that do not have debiliating side effects. The firm's approach is centered on the idea of targeting the activity of a protein called eIF4E for neuropathic pain treatment. For over a decade, the lab of one of the firm's founders has studied elF4E and demonstrated the key role the protein plays in regulating the activity of pain-sensing neurons in the peripheral nervous system called nociceptors: neurons play a crucial role in neuropathic pain. The effort is centered on optimizing therapeutic targeting of eIF4E for the treatment of neuropathic pain with the goal of advancing a lead molecule to Investigational New Drug (IND) status in timely manner.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2023 2 NIH $7,126,295
Project Title: Development and Optimization of MNK Inhibitors for the Treatment of Neuropathic Pain

Key People / Management

  Craig Benson -- CEO

  Joe Price -- Co-Founder, President & Chairman

  Suzanne Macgillivray -- Grants Accountant & Administrator

  Ted Price -- Co-Founder

  James Jeffrey Sahn -- Vice President of Drug Development

Company News

There are no news available.